HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

338.00p
   
  • Change Today:
      25.00p
  • 52 Week High: 346.00
  • 52 Week Low: 173.60
  • Currency: UK Pounds
  • Shares Issued: 871.26m
  • Volume: 343,723
  • Market Cap: £2,944.85m
  • RiskGrade: 226

ShareCast News

Hutchmed refocuses strategy away from early-stag... 15-Nov-2022 ShareCast
Hutchmed reports positive results from recent fr... 14-Nov-2022 ShareCast
Hutchmed upbeat on latest study results for colo... 08-Aug-2022 ShareCast
Hutchmed China confident after being added to SE... 31-Mar-2022 ShareCast
Hutchmed China losses widen as it appoints new CEO 03-Mar-2022 ShareCast
Two Hutchmed drugs included in China's 2022 reim... 03-Dec-2021 ShareCast
Hutchmed strikes collaboration deal with Epizyme 09-Aug-2021 ShareCast
Hutchmed makes first commercial sale of 'Orpathy... 13-Jul-2021 ShareCast
Hutchmed China launches Hong Kong public offering 18-Jun-2021 ShareCast
Hutchison Chi-Med begins latest trial of fruquin... 04-Sep-2020 ShareCast
Hutchison Chi-Med begins phase 1 study of 'HMPL-... 24-Jul-2020 ShareCast
Hutchison Chi-Med gets FDA fast track approval f... 18-Jun-2020 ShareCast
Hutchison Chi-Med venture to surrender unused la... 09-Jun-2020 ShareCast
Hutchison Chi-Med shares up on updated results f... 10-Feb-2020 ShareCast
Hutchison Chi-Med upbeat on progress with surufa... 20-Jan-2020 ShareCast
Hutchison Chi-Med gets priority review for 'suru... 20-Dec-2019 ShareCast
Hutchison China Meditech expands collaboration w... 10-Oct-2019 ShareCast
Hutchison Chi-Med initiates latest study of HMPL... 04-Oct-2019 ShareCast
Hutchison China MediTech launches trial for auto... 23-Aug-2019 ShareCast
Hutchison Chi-Med makes progress with surufatinib 14-Jun-2019 ShareCast
Hutchison loss widens as China legislation hampe... 11-Mar-2019 ShareCast
Hutchison Chi-Med enters four new drug test coll... 29-Nov-2018 ShareCast
Fruquintinib fails to meet primary endpoint in l... 16-Nov-2018 ShareCast
Chi-Med disappointed as lung cancer treatment fa... 16-Nov-2018 ShareCast
Hutchison seeks approval for cancer drug after t... 12-Mar-2018 ShareCast
Hutchison Chi-Med begins fruquintinib trial in US 15-Dec-2017 ShareCast
Hutchison Chi-Med launches new clinical trial of... 31-Oct-2017 ShareCast
Hutchison Chi-Med confirms ADS pricing for $262m... 26-Oct-2017 ShareCast
Chi-Med trials with AstraZeneca show preliminary... 17-Oct-2017 ShareCast
Hutchison Chi-Med upbeat on latest Iressa trial ... 16-Oct-2017 ShareCast
Hutchison China MediTech on the up as it announc... 03-Mar-2017 ShareCast
Hutchison China MediTech presents promising data... 14-Nov-2016 ShareCast
Hutchison China's JV receives $60m land compensa... 31-Oct-2016 ShareCast
Director dealings: Chi-Med director's wife bags ... 09-Aug-2016 ShareCast
Chi-Med revenue ahead, but investments kill most... 02-Aug-2016 ShareCast
Chi-Med expands TATTON Phase II trial 20-Jun-2016 ShareCast
Chi-Med launches fruquintinib trial in China 13-May-2016 ShareCast
Director dealing: Somero CEO sells half stake fo... 21-Mar-2016 ShareCast
Results Round-up 28-Jul-2015 ShareCast
Hutchison China first-half profit drops as resea... 28-Jul-2015 ShareCast
Hutchison China Meditech chairman buys £0.8m wor... 08-Apr-2015 ShareCast
To dips in at Hutchinson China-Meditech 20-Nov-2014 ShareCast
Wednesday broker round-up UPDATE 30-Jul-2014 ShareCast
Monday broker round-up UPDATE 19-May-2014 ShareCast
Wednesday broker round-up UPDATE 02-Apr-2014 ShareCast
Friday broker round-up UPDATE 14-Mar-2014 ShareCast
Hutchison China MediPharma director takes stake ... 16-Oct-2013 ShareCast
Hutchison signs Chinese licensing and marketing ... 09-Oct-2013 ShareCast
Wednesday broker round-up UPDATE 09-Oct-2013 ShareCast
Inmarsat Chairman sells 1.4m pounds-worth of sha... 08-Aug-2013 ShareCast

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HCM Market Data

Currency UK Pounds
Share Price 338.00p
Change Today 25.00p
% Change 7.99 %
52 Week High 346.00
52 Week Low 173.60
Volume 343,723
Shares Issued 871.26m
Market Cap £2,944.85m
RiskGrade 226

HCM Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
73.61% below the market average73.61% below the market average73.61% below the market average73.61% below the market average73.61% below the market average
56.86% below the sector average56.86% below the sector average56.86% below the sector average56.86% below the sector average56.86% below the sector average
Price Trend
51.07% above the market average51.07% above the market average51.07% above the market average51.07% above the market average51.07% above the market average
85.45% above the sector average85.45% above the sector average85.45% above the sector average85.45% above the sector average85.45% above the sector average
Income Not Available
Growth
67.21% above the market average67.21% above the market average67.21% above the market average67.21% above the market average67.21% above the market average
88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average

HCM Dividends

No dividends found

Trades for 09-May-2024

Time Volume / Share Price
16:38 200 @ 338.00p
16:36 1,000 @ 338.00p
16:36 1,000 @ 338.00p
16:35 1,000 @ 338.00p
16:35 500 @ 338.00p

HCM Key Personnel

CEO Weiguo Su

Top of Page